Holen Sie sich die Stockscreener-App
66.17
1.98%
-1.34
Handel nachbörslich:
66.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$67.51
Offen:
$67.76
24-Stunden-Volumen:
1.15M
Relative Volume:
0.68
Marktkapitalisierung:
$6.24B
Einnahmen:
$536.20M
Nettoeinkommen (Verlust:
$-45.64M
KGV:
-123.73
EPS:
-0.5348
Netto-Cashflow:
$-28.94M
1W Leistung:
+1.36%
1M Leistung:
+9.90%
6M Leistung:
+132.42%
1J Leistung:
+164.68%
1-Tages-Spanne:
$66.11
$68.73
1-Wochen-Bereich:
$63.48
$68.73
52-Wochen-Spanne:
$22.05
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
66.17 | 6.24B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 68.25 USD - Investing.com
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics' Outlook Brightens As Turnaround Looms - Investor's Business Daily
FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari - Medical Marketing and Media
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Seong Chi: Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies - Oncodaily
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting - Kalkine Media
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 67.97 USD - Investing.com
Responsive Playbooks and the TVTX Inflection - Stock Traders Daily
Travere (NASDAQ: TVTX) CFO executes tax-withholding stock sale - Stock Titan
TVTX | Travere Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com - Investing.com South Africa
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations - Sahm
Travere Therapeutics stock hits 52-week high at 66.35 USD - Investing.com
Travere Therapeutics (TVTX) director sells 10K shares under 10b5-1 plan - Stock Titan
Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX) - Seeking Alpha
US High Growth Tech Stocks To Watch In August 2026 - Sahm
Travere Therapeutics (NASDAQ: TVTX) director plans 5,000-share sale tied to stock options - Stock Titan
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline - Yahoo Finance
Travere Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Travere Therapeutics (TVTX) Advances 3.12% to $64.08, Approaching Key Resistance at $67.28Dark Pool Sentiment - vinanet.vn
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript - AOL.com
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A - Stock Titan
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net LossHas The Bull Case Changed? - webull.com
(TVTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $74.62, Implies 20% Upside - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Bank of America Corp (TVTX) discloses 5.8% beneficial stake in Travere Therapeutics - Stock Titan
What is HC Wainwright's Estimate for TVTX Q3 Earnings? - marketbeat.com
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP - MarketBeat
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):